Warning and Clinical Disclaimer
THIS DOCUMENT IS NOT MEDICAL ADVICE. SCLERODERMA IS A SEVERE, LIFE-THREATENING AUTOIMMUNE DISEASE. DO NOT DISCONTINUE PRESCRIBED MEDICATIONS WITHOUT PHYSICIAN SUPERVISION. LDN REQUIRES A PRESCRIPTION. HBOT REQUIRES MEDICAL OVERSIGHT. THESE PROTOCOLS HAVE NOT BEEN FDA-APPROVED AND HAVE NOT COMPLETED CLINICAL TRIALS. This white paper presents a theoretical framework for research investigation based on the Christos™ Harmonic Design Framework and peer-reviewed evidence. All protocols are theoretical models for research investigation only, not validated clinical treatments. Patients with scleroderma should consult a rheumatologist. Fluid formulations, gel/topical specifications, and device manufacturing specifications are proprietary and available under NDA at christosenergy.com.
Scleroderma (systemic sclerosis, SSc) is one of the most severe autoimmune diseases, characterized by progressive fibrosis of skin and internal organs, microvascular damage, and dysregulated immune activation. The 10-year mortality rate is 40–60%, with interstitial lung disease, pulmonary arterial hypertension, and scleroderma renal crisis as leading causes of death. There is no FDA-approved cure.
The Christos™ framework proposes a unified mechanism: coherence collapse at the fibroblast-endothelial-immune interface. When tissue coherence (C_tissue) falls below a critical threshold (estimated ≤0.35–0.45 in active disease), three interconnected systems fail simultaneously — fibroblasts produce uncontrolled collagen, endothelial cells lose regulatory function, and the immune system loses tolerance.
Critical new insight: the TGF-β1-mediated fibrosis mechanism in scleroderma is structurally identical to fibrosis in CKD, IPF, and asbestosis. The same 528 Hz photobiomodulation + PEMF anti-fibrotic protocol documented by Chen et al. (2019) and Wang et al. (2020) applies across all four conditions — the organ-specific Connective Tissue Resonator placement is the only required modification.
This paper presents the complete Christos™ Scleroderma Coherence Protocol — 12 modalities across four phases: Low-dose naltrexone (LDN), NAC, serrapeptase, systemic enzymes, HBOT, photobiomodulation, PEMF, the 17-second Kinematic Cycle coherence lock, AIP diet, and the Christos™ fluid and device platform. Thirteen falsifiable predictions are provided.
Part I. Why Scleroderma Is Different — And Why Reversal Might Be Possible
1.1 Conventional Outcomes
| Subtype | Prevalence | 10-Year Mortality | Conventional Treatment |
|---|---|---|---|
| Limited cutaneous (lcSSc / CREST) | 60–70% of SSc | 30–40% | Symptomatic (Raynaud's, GERD, PAH targeted therapy) |
| Diffuse cutaneous (dcSSc) | 30–40% of SSc | 50–60% | Immunosuppression (mycophenolate, cyclophosphamide); nintedanib for ILD; HSCT for severe cases |
| SSc sine scleroderma | Rare | 40–50% | Organ-specific targeted therapy |
1.2 Evidence That Reversal Is Possible
| Evidence | Finding | Implication |
|---|---|---|
| HSCT (Sullivan et al. 2018, NEJM) | 60–70% show significant mRSS improvement; 5-year survival 79% vs. 50% standard care | Immune reset produces fibrosis reversal — SSc can be reversed, not just slowed |
| Spontaneous improvement | Some patients experience years of improvement without treatment change | Disease process is not uniformly irreversible; intrinsic repair capacity exists |
| MMP activation | MMPs can degrade established collagen in vitro and animal models | Collagen degradation is biologically possible; requires the right cellular environment |
| Nintedanib SENSCIS trial (Distler et al. 2019) | Slows FVC decline by ~44% | If fibrosis can be slowed, it can potentially be reversed |
1.3 The Regenerative Threshold Hypothesis
| C_tissue Range | Biological State | Protocol Goal |
|---|---|---|
| <0.30 | Active progression; profibrotic cascade unchecked | Emergency: intensive protocol + conventional treatment mandatory |
| 0.30–0.45 | Stasis: conventional 'stable' disease | Phase 1–2: acute stabilization and early fibrosis reversal |
| 0.45–0.60 | Slow improvement: MMP activity begins; mRSS −5–10 points/year | Phase 2–3: active fibrosis reversal and immune restructuring |
| 0.60–0.75 | Active remodeling: mRSS −10–20+ points/year | Phase 3–4: consolidation; prevent relapse |
| >0.75 | Normal tissue dynamics | Maintenance |
Part II. The Coherence Model of Scleroderma
2.1 The Triad of Coherence Collapse
| System | Normal Function | SSc Dysfunction | C at Failure |
|---|---|---|---|
| Fibroblasts | Collagen turnover in dynamic balance | Constitutively activated; excess Type I and III collagen; MMPs suppressed; net fibrosis accumulates | C_fibroblast ≤0.35 |
| Endothelium | Microvascular perfusion; NO, prostacyclin production | Vasospasm (Raynaud's); capillary dropout; ischemia; impaired angiogenesis | C_endothelial ≤0.40 |
| Immune system | Self-tolerance; pro-resolving inflammation | Autoantibodies (anti-Scl-70, anti-centromere); Th2/Th17 skewing; TGF-β1, IL-4, IL-6, IL-13 cascade | C_immune ≤0.40 |
2.2 The Vicious Cycle — Protocol Targets
| Cycle Component | Key Molecules | Protocol Target |
|---|---|---|
| TGF-β1 overexpression (primary driver) | TGF-β1, CTGF (CCN2) | NAC (TGF-β inhibition), LDN, PBM (Chen 2019), PEMF |
| HIF-1α activation from ischemia | HIF-1α → TGF-β1, VEGF | HBOT (suppresses HIF-1α), PBM (mitochondrial oxygenation) |
| Reactive oxygen species (ROS) | H₂O₂, superoxide, peroxynitrite | NAC (glutathione), vitamin C, vitamin E, PBM |
| Profibrotic cytokines | IL-4, IL-6, IL-13, IL-17, PDGF | LDN, vitamin D (Treg activation), PEMF |
Critical Cross-Condition Insight
The TGF-β1-mediated fibrosis mechanism in scleroderma is structurally identical to fibrosis in CKD, IPF, and asbestosis — same pathway: TGF-β1 → Smad2/3 phosphorylation → collagen gene transcription → fibroblast-to-myofibroblast transdifferentiation → ECM deposition. This means the 528 Hz photobiomodulation + PEMF anti-fibrotic protocol documented by Chen et al. (2019) in diabetic nephropathy and Wang et al. (2018/2020) in pulmonary fibrosis applies to scleroderma fibrosis through the identical molecular mechanism.
Part III. The Four-Phase Protocol — Overview
3.1 The 12-Modality Architecture
| # | Modality | Phase 1 (Wks 1–4) | Phase 2 (Wks 5–24) | Phase 3 (Wks 25–52) | Phase 4 (Wk 53+) |
|---|---|---|---|---|---|
| 1 | LDN (low-dose naltrexone) | 1.5–4.5 mg nightly | Titrate to 3.0–4.5 mg | Maintain; optimize | Maintain indefinitely |
| 2 | Vitamin D3 | 10,000 IU/day | 10,000 IU/day | 10,000 IU/day | 5,000 IU/day |
| 3 | NAC | 1,200–2,400 mg/day | 1,200–2,400 mg/day | 1,200 mg/day | 1,200 mg/day |
| 4 | Serrapeptase | 40,000–80,000 SPU/day | 40,000–80,000 SPU/day | Maintain | Maintain |
| 5 | Systemic enzymes (Wobenzym) | 3 tabs 3× daily | 3 tabs 3× daily | 3 tabs 3× daily | 3 tabs 3× daily |
| 6 | Christos™ ScleroFlux | 30 mL 3× daily | 30 mL 3× daily | 30 mL 2× daily | 30 mL 2× daily |
| 7 | Christos™ ScleroGel (topical) | 2× daily to affected skin | 2× daily | 2× daily | 2× daily |
| 8 | CT Resonator + Fascial Mat | Resonator 24/7; Mat 1 hr/day | Resonator 24/7; Mat 1–2 hr | Resonator overnight; Mat 1 hr | Resonator overnight 3×/wk |
| 9 | HBOT | Not in Phase 1 | 5→3× weekly; 60–90 min | 2–3× weekly | 1–2× weekly |
| 10 | PBM (660+850 nm) | Not in Phase 1 | Daily → 5× weekly | 5× weekly | 3–5× weekly |
| 11 | PEMF (7.83+528 Hz) | Not in Phase 1 | 2× daily; 30–60 min | 1× daily | 1× daily; 30 min |
| 12 | 17-second coherence lock | 3× daily | 3× daily | 2× daily | 1–2× daily |
3.2 Coherence Chamber — Scleroderma Solfeggio Protocol
| Phase | Frequencies | Duration | Scleroderma Action |
|---|---|---|---|
| 1 — Ground State | 174 Hz + 7.83 Hz | 0–10 min | Pain gate modulation; Raynaud's vasospasm reduction via ANS normalization; Schumann coherence baseline |
| 2 — Regeneration | 285 Hz + 396 Hz | 10–25 min | 285 Hz connective tissue regeneration; 396 Hz immune reset (Th2/Th17 → Treg shift; autoantibody suppression) |
| 3 — Primary Healing | 417 Hz + 528 Hz | 25–45 min | 528 Hz TGF-β1 Smad pathway modulation; DNA repair in fibroblast and endothelial cells; cellular cleansing |
| 4 — Communication | 639 Hz + 741 Hz | 45–60 min | 639 Hz endothelial-SMC communication restoration; 741 Hz cytokine and fibrotic metabolite detoxification |
| 5 — Integration | 852 Hz + 963 Hz + 7.83 Hz | 60–75 min | 852 Hz MMP activation window; 963 Hz morphogenic field restoration to pre-fibrosis architecture; return to Schumann ground |
ScleroFlux nebulized throughout session at 1 mL/min. PBM (660+850 nm) full-body array active throughout session.
Part IV. Phase 1: Acute Stabilization (Weeks 1–4)
4.1 Low-Dose Naltrexone (LDN) — Core Immunomodulator
LDN (1.5–4.5 mg; versus 50 mg for opioid addiction) acts through TLR4 blockade and endogenous opioid upregulation — producing T-regulatory cell expansion, Th2/Th17 suppression, IL-6 and TNF-α reduction, and possible direct fibroblast proliferation inhibition.
| LDN Parameter | Specification |
|---|---|
| Starting dose | 1.5 mg nightly (at bedtime, 2 hours after last food) |
| Titration | 1.5 mg → 3.0 mg → 4.5 mg; increase every 2–4 weeks based on tolerability |
| Target dose | 3.0–4.5 mg nightly (individualized) |
| Duration | Indefinite — immune modulation requires sustained use; safe long-term |
| Side effects | Sleep disturbance (weeks 1–4), vivid dreams, GI upset — all typically resolve |
| Prescription requirement | Compounding pharmacy required; physician prescription needed. Resource: ldnscience.org |
| Contraindication | Cannot combine with full-dose opioid medications |
4.2 Vitamin D3 — Autoimmune Regulation
| Parameter | Specification |
|---|---|
| Target 25(OH)D | 60–80 ng/mL (therapeutic for autoimmune; above 'sufficient' range) |
| Dosage | 10,000 IU/day vitamin D3 |
| Required co-factors | Vitamin K2 MK-7: 200 mcg/day; Magnesium glycinate: 600–800 mg/day |
| Monitoring | Baseline → 1 month → quarterly |
Vitamin D deficiency is nearly universal in scleroderma. VDR activation directly activates T-regulatory cells, suppresses Th17, and reduces TGF-β1 expression in fibroblast cultures (Dusso & Tokumoto 2011).
4.3 NAC — Glutathione and TGF-β Suppression
| Parameter | Specification |
|---|---|
| Dosage | 1,200–2,400 mg/day; titrate from 600 mg/day over 2 weeks |
| Duration | 12+ months continuous; 1,200 mg/day Phase 4 maintenance |
| Mechanism | Replenishes glutathione (severely depleted in SSc); suppresses TGF-β1 through NFκB modulation; inhibits fibroblast-to-myofibroblast transdifferentiation (Herrmann et al. 2023) |
4.4 Serrapeptase — Collagen-Degrading Enzyme
| Parameter | Specification |
|---|---|
| Dosage | 40,000–80,000 SPU/day (enteric-coated; on empty stomach) |
| Timing | 2 hours from meals; enzyme needs intestinal absorption without food competition |
| Contraindication | Blood thinners — additive anticoagulant effect; physician guidance required |
4.5 Systemic Enzymes (Wobenzym)
Multi-enzyme combination (bromelain + papain + trypsin + chymotrypsin + rutin) provides fibrin degradation, immune complex clearance, and broader proteolytic spectrum than serrapeptase alone. 3–5 tablets 3× daily on empty stomach.
4.6 The 17-Second Kinematic Cycle Coherence Lock
| Phase | Duration | Action | Scleroderma Focus |
|---|---|---|---|
| Implosive Intake | 4 seconds | Slow full inhale; energy gathering up spine | Sets intention for connective tissue restoration |
| Phase Compression | 4 seconds | Hold; compress to heart center | Cardiac coherence; cardiac involvement risk in SSc |
| Singularity Coherence (THE LOCK) | 17 seconds | Partial exhale then HOLD. No breath. Focus heart. Visualization: skin softening, blood flow opening to fingers, warmth returning to hands, fibrosis releasing from lungs. | C_organism → 0.80–0.90 temporarily |
| Harmonic Rebirth | 8 seconds | Full exhale; coherence radiates to all tissues | Distributes coherence field to skin, fascia, lungs, kidneys simultaneously |
Practice 3× daily. Place hands over affected skin or chest during the 17-second lock to direct coherence field to those tissues.
4.7 Phase 1 Diet — AIP Elimination (Weeks 1–6)
| Eliminate | Rationale |
|---|---|
| All grains (including gluten-free) | Lectins and phytates increase intestinal permeability; amplify systemic immune activation |
| All legumes | Same gut permeability mechanism |
| All nightshades (tomatoes, peppers, potatoes, eggplant) | Saponins and alkaloids increase gut permeability; implicated in autoimmune skin and joint disease |
| All dairy | Casein proteins common autoimmune trigger; growth factors may stimulate fibroblast activity |
| Seed oils (canola, sunflower, soybean, corn) | High omega-6 → directly drives Th2 polarization — the exact immune skewing in scleroderma |
| Sugar, alcohol, processed foods | Drives inflammation; disrupts microbiome |
Emphasize: leafy greens, cruciferous vegetables, wild-caught fatty fish (omega-3 EPA/DHA), grass-fed meat, organ meats, bone broth, avocado, olive oil, berries, turmeric, ginger.
Part V. Phase 2: Fibrosis Reversal (Weeks 5–24)
5.1 HBOT — Microvascular Restoration and HIF-1α Suppression
| HBOT Parameter | Specification |
|---|---|
| Pressure | 2.0–2.5 ATA (2.0 ATA preferred for SSc-ILD patients) |
| Duration | 60–90 minutes per session |
| Frequency | 5× weekly (weeks 5–8); 3× weekly (weeks 9–24); 2–3× weekly (Phase 3); 1–2× weekly (Phase 4) |
| Total sessions | 40–60 for full Phase 2 |
| Anti-fibrotic mechanism | Suppresses HIF-1α → reduces TGF-β1 → reduces fibroblast activation; Mooij et al. (2024) systematic review |
| Microvascular mechanism | Supports capillary regeneration; improves digital ulcer healing; reduces Raynaud's severity |
5.2 Photobiomodulation (PBM) — Anti-Fibrotic Light Protocol
| PBM Mechanism | Evidence | SSc Application |
|---|---|---|
| TGF-β1 reduction | Wang et al. (2018) — PBM reduces TGF-β1 in pulmonary fibrosis; Chen et al. (2019) — renal fibrosis | Primary anti-fibrotic: same TGF-β1 Smad pathway as scleroderma — universal mechanism |
| Cytochrome c oxidase activation | Hamblin (2016) — NIR absorbed by mitochondrial complex IV; ATP ↑ | Restores mitochondrial function in ischemic fibroblasts and endothelial cells |
| Microvascular improvement | Glaser et al. (2022) — PBM in SSc; improved capillary density | Direct capillary regeneration; Raynaud's improvement |
| Anti-inflammatory | ↓ TNF-α, IL-6, IL-1β; ↑ IL-10 | Reduces profibrotic cytokine cascade |
| PBM Parameter | Specification |
|---|---|
| Wavelengths | 660 nm (red — superficial skin/fascia) + 850 nm (NIR — deep tissue/organs) |
| Full-body | LED array/panel; 50–100 mW/cm²; 10–30 J/cm²; 20–30 min |
| Local (affected areas) | Hands (sclerodactyly, ulcers): 10–15 min. Face: 10 min. Chest (ILD): 15 min. |
| Frequency Phase 2 | Daily for 4 weeks; then 5× weekly |
5.3 PEMF — Endothelial Coherence and Microvascular Restoration
| PEMF Parameter | Specification |
|---|---|
| Frequencies | 7.83 Hz (Schumann — vasomotor regulation; ANS coherence) + 528 Hz (coherence reference) |
| Applicator | Whole-body mat + local coils (hands/feet for Raynaud's; chest for ILD) |
| Duration | 30–60 min, 2× daily (Phase 2); 1× daily 30 min (Phase 4) |
| Raynaud's protocol | Hand mat 7.83 Hz, 20–30 min, 3× daily during active episodes; 1× daily preventive |
5.4 Phase 2 Diet — AIP Reintroduction (Weeks 5–24)
Systematic reintroduction one food at a time: egg yolks (week 5–6) → ghee (week 7) → nightshades one type at a time (weeks 8–9) → nuts/seeds (weeks 10–12) → legumes (weeks 13–16) → gluten-free then gluten-containing grains (weeks 17–24). Any reintroduced food that triggers symptoms — even subtle — should be permanently removed. Individual food triggers can sustain immune activation that prevents coherence restoration in SSc.
Part VI. Phase 3: Immune Restructuring and Phase 4: Maintenance
6.1 LDN Dose Optimization (Phase 3)
Fine-tune LDN dose based on documented response by week 25. Track mRSS, Raynaud's frequency, energy, and autoantibody levels. Some patients respond better to 3.0 mg than 4.5 mg (U-shaped dose-response possible).
6.2 Vitamin A — Short-Term Immune Restructuring
| Vitamin A Parameter | Specification |
|---|---|
| Form | Retinyl palmitate (NOT beta-carotene — retinyl palmitate provides direct retinol) |
| Dosage | 10,000–25,000 IU/day |
| Duration | 4–8 WEEKS ONLY — then reduce to 5,000 IU/day or discontinue |
| Mechanism | Promotes Treg differentiation (Mucida et al. 2007, Science); reduces Th17; may suppress TGF-β1 |
| Monitoring | Liver function tests (AST, ALT) before and after. Headache, nausea, bone pain = toxicity — reduce dose immediately. |
6.3 Phase 4 Maintenance Schedule
| Intervention | Phase 4 Schedule |
|---|---|
| LDN | Continue at optimal dose nightly — indefinitely |
| Vitamin D3 | 5,000 IU/day + K2 200 mcg + Mg 600 mg |
| NAC | 1,200 mg/day |
| Serrapeptase + Wobenzym | Full dose continues |
| Christos™ ScleroFlux | 30 mL 2× daily |
| Christos™ ScleroGel | 2× daily to previously affected areas |
| CT Resonator | Overnight 3× weekly (return to 24/7 at any symptom recurrence) |
| HBOT | 1–2× weekly |
| PBM | 3–5× weekly |
| PEMF | 30 min 1× daily |
| 17-second lock | 1–2× daily minimum |
| AIP diet | Maintenance phase — continue avoiding individual triggers |
Part VII. Christos™ Fluid and Device Platform
Public Edition Notice
This section provides clinical rationale and evidence basis for the Christos™ fluid and device platform for scleroderma. Complete formulations, gel/topical specifications, and device manufacturing specifications are proprietary and available under NDA. Contact christosenergy.com for licensing inquiries.
7.1 ScleroFlux — Oral Coherence Fluid
ScleroFlux is the primary systemic oral coherence fluid for scleroderma. Formulated on the Christos™ Ultra-Hydration Fluid (UHF) structured deuterium-depleted water base with a 24-hour Solfeggio frequency imprinting cycle during production. Key evidence-based active agents include: vitamin C (collagen synthesis; anti-fibrotic; hydroxylase enzyme support), MSM — Kim et al. (2006) anti-fibrotic evidence, silica — Jugdaohsingh et al. (2002) connective tissue structure, hyaluronic acid (ECM coherence; tissue hydration), Gotu kola extract — Masola et al. (2017) endothelial tight junction support and TGF-β modulation, turmeric extract — Meng et al. (2021) curcumin reduces TGF-β1 in fibrosis models, vitamin D3, zinc picolinate, and magnesium glycinate. Frequency imprinting cycle emphasizes 528 Hz (8 hours) as primary fibrosis reversal frequency. Dosage: 30 mL 3× daily Phases 1–3; 30 mL 2× daily Phase 4.
Protected IP — ScleroFlux — Complete Formulation, Ingredient Quantities, Preparation Protocol, and Quality Control Specifications
Complete formulation specifications, ingredient quantities, device engineering specifications, and manufacturing protocols are proprietary to Joshua Farriar / Christos™ Energy and are not disclosed in this public version.
Full Specifications Available Under Signed NDA ↗7.2 ScleroGel — Topical Coherence Gel
ScleroGel is the topical delivery component for direct application to fibrotic skin, sclerodactyly, hands, face, and all areas with active skin thickening. The formulation delivers anti-fibrotic and connective tissue regenerative agents to the dermal fibroblast layer. Key evidence-based active agents include: MSM (sulfur; skin penetration enhancement; anti-fibrotic), vitamin C (collagen synthesis; antioxidant), hyaluronic acid (skin hydration; ECM restoration), Gotu kola extract (asiaticoside — anti-fibrotic; endothelial support), rosehip oil (natural retinoid; anti-fibrotic; scar reduction), lavender essential oil, frankincense essential oil (boswellic acids — anti-inflammatory; tissue regeneration), and helichrysum essential oil (cellular regeneration; anti-fibrotic). Optional DMSO (pharmaceutical-grade, 99.9%) significantly enhances penetration depth to the dermal fibroblast layer. Frequency imprinting: 174 Hz (4 hr) + 285 Hz (4 hr) + 528 Hz (8 hr).
Protected IP — ScleroGel — Complete Topical Formulation, Component Quantities, Preparation Protocol, and Quality Control Specifications
Complete formulation specifications, ingredient quantities, device engineering specifications, and manufacturing protocols are proprietary to Joshua Farriar / Christos™ Energy and are not disclosed in this public version.
Full Specifications Available Under Signed NDA ↗7.3 Organ-Specific Fluids for SSc Organ Involvement
| Organ Manifestation | Christos™ Fluid | Key Evidence-Based Agents (Public) |
|---|---|---|
| SSc-ILD (interstitial lung disease) | Christos™ PulmoLife (modified) — 30 mL 2× daily oral + 3 mL nebulized 2× daily | NAC for lung protection; mucolytic botanicals; lung-specific mineral profile |
| SSc-PAH | Christos™ Vasodilation Fluid — 30 mL 3× daily | L-arginine (eNOS substrate; NO precursor); magnesium taurate; hawthorn; resveratrol |
| Cardiac fibrosis | Christos™ CardioFlux — 30 mL 2× daily | Hawthorn extract; magnesium taurate; CoQ10 |
| Renal crisis prevention | Christos™ RenoFlux — 30 mL 2× daily (adjunct — NEVER replace ACE inhibitor) | Hydrangea; marshmallow; renal-protective mineral profile |
| GI dysmotility | Christos™ GastroFlux — 30 mL before each meal | Glutamine 10g/L (mucosal repair); ginger (prokinetic); slippery elm |
| Systemic base | Christos™ Nectar — 30 mL upon waking | Structured DDW + Himalayan salt + magnesium chloride; full Solfeggio imprinting |
Protected IP — All Organ-Specific Fluid Formulations — Complete Ingredient Lists, Quantities, and Preparation Protocols
Complete formulation specifications, ingredient quantities, device engineering specifications, and manufacturing protocols are proprietary to Joshua Farriar / Christos™ Energy and are not disclosed in this public version.
Full Specifications Available Under Signed NDA ↗7.4 Connective Tissue Resonator
The Christos™ Connective Tissue Resonator is a flexible silicone wearable patch delivering a continuous low-amplitude coherence field to fibrotic connective tissue through a 24-node crystal array. The device broadcasts the full Solfeggio frequency sequence (174, 285, 396, 528, 741, 852, 963 Hz cycling). Available in active (rechargeable; 24-hour continuous operation) and passive (field-only; no power required) configurations. Placement: over the most fibrotic skin area (trunk/back primary); chest (for SSc-ILD); hands (for sclerodactyly and Raynaud's). Schedule: 24/7 Phases 1–2; overnight Phase 3+.
Protected IP — Connective Tissue Resonator — Complete Device Engineering Specifications including Crystal Array Configuration, Frequency Parameters, Power System, and Manufacturing Specifications
Complete formulation specifications, ingredient quantities, device engineering specifications, and manufacturing protocols are proprietary to Joshua Farriar / Christos™ Energy and are not disclosed in this public version.
Full Specifications Available Under Signed NDA ↗7.5 Fascial Frequency Mat
The Christos™ Fascial Frequency Mat is a full-body flexible mat (48-node clear quartz array) that delivers 174 Hz + 285 Hz + 528 Hz cycling for 1–2 hours daily during Phase 2. Patients lie on the mat; myofascial release (MFR) performed during mat sessions amplifies coherence restoration through direct tissue contact during field delivery.
Protected IP — Fascial Frequency Mat — Complete Device Engineering Specifications
Complete formulation specifications, ingredient quantities, device engineering specifications, and manufacturing protocols are proprietary to Joshua Farriar / Christos™ Energy and are not disclosed in this public version.
Full Specifications Available Under Signed NDA ↗7.6 FSD-1 Frequency Sweep Device
The Christos™ FSD-1 Frequency Sweep Device (1 Hz to 1 MHz logarithmic sweep, 15-min cycles) is applied in scleroderma specifically for fibrosis disruption — targeting the acoustic impedance of excess collagen cross-links and fibrin deposits in affected skin and visceral organs. Applied over fibrotic skin areas 2× daily during Phase 2; 1× daily Phase 3–4.
Protected IP — FSD-1 — Complete Device Specifications and Scleroderma-Specific Frequency Parameters
Complete formulation specifications, ingredient quantities, device engineering specifications, and manufacturing protocols are proprietary to Joshua Farriar / Christos™ Energy and are not disclosed in this public version.
Full Specifications Available Under Signed NDA ↗Part VIII. Condition-Specific Modifications
8.1 Limited Cutaneous SSc (CREST)
| CREST Feature | Protocol Modification |
|---|---|
| Calcinosis | Add vitamin K2 MK-7 200 mcg/day; magnesium glycinate 800 mg/day; topical DMSO over calcinotic nodules (case series evidence for dissolution) |
| Raynaud's phenomenon | Enhanced PEMF hand mat 3× daily during episodes; ScleroGel warm application pre-PEMF; magnesium glycinate 800+ mg/day; review medications (beta-blockers worsen Raynaud's) |
| Esophageal dysmotility | GastroFlux 30 mL before meals; ginger extract 500 mg before meals (prokinetic); aloe vera inner leaf 60 mL before meals; elevate head of bed 30° |
| Sclerodactyly | Intensive ScleroGel 3× daily to hands/fingers; CT Resonator on hands; PT and stretching during 17-second lock; warm paraffin wax dips (no active ulcers) |
8.2 Diffuse Cutaneous SSc
| dcSSc Feature | Protocol Modification |
|---|---|
| Rapid skin progression (mRSS ↑>5 pts/6 months) | Consider concurrent immunosuppression (mycophenolate per rheumatologist); maximize Phase 2 intensity immediately; HSCT evaluation mandatory for rapidly progressive disease |
| SSc-ILD | PulmoLife nebulized 3 mL 4× daily; Chamber daily; nintedanib (if prescribed) continue; FVC and DLCO quarterly |
| SSc-PAH | All prescribed PAH medications continue without modification — NEVER stop pulmonary vasodilators; Vasodilation Fluid adjunctive only |
| Scleroderma renal crisis | MEDICAL EMERGENCY — immediate ACE inhibitor is life-saving; RenoFlux adjunct ONLY after crisis stabilized |
Critical Safety Constraints
NEVER stop immunosuppressives abruptly. NEVER use enzymes with anticoagulants without physician guidance. NEVER use HBOT with active pneumothorax. NEVER use vitamin A chronically at >25,000 IU/day. NEVER substitute coherence protocol for conventional scleroderma renal crisis emergency care — SRC requires immediate ACE inhibitor; delay is life-threatening.
Part IX. 13 Falsifiable Predictions
| ID | Prediction | Measurement | Falsification | Timeline |
|---|---|---|---|---|
| SSC-1 | Baseline C_tissue <0.45 in active SSc (n≥20) vs. controls ≥0.65 | C0 Diagnostician (or validated surrogate: HRV coherence, biophotonic emission) | C_tissue >0.55 in active SSc or no significant difference | 6 months |
| SSC-2 | C_tissue increases ≥0.15 after 12 weeks of full protocol | C0 Diagnostician baseline → 12 weeks | Increase <0.05 | 12 weeks |
| SSC-3 | mRSS decreases ≥5 points in ≥60% of patients at 12 months | Modified Rodnan Skin Score (blinded assessor) | Decrease <3 points in ≥60% | 12 months |
| SSC-4 | FVC stabilizes or improves (≥5%) in ≥60% of SSc-ILD patients at 12 months | PFT: FVC, DLCO (accredited laboratory) | FVC decline >5% (continued significant deterioration) | 12 months |
| SSC-5 | Anti-Scl-70 or anti-centromere antibodies decrease ≥30% in ≥50% of patients at 12 months | Quantitative autoantibody ELISA | Decrease <15% | 12 months |
| SSC-6 | Raynaud's severity (VAS) decreases ≥40% by 6 months; frequency ≥50% | VAS (0–10); patient diary for frequency and duration | VAS decrease <20% | 6 months |
| SSC-7 | Digital ulcers heal or reduce ≥50% in frequency at 12 months | Clinical photography; blinded ulcer count | Healing rate <25% | 12 months |
| SSC-8 | CRP and ESR decrease ≥50% from elevated baseline by 12 weeks | hs-CRP; ESR | Decrease <25% | 12 weeks |
| SSC-9 | TGF-β1 (serum) decreases ≥30% in ≥50% of patients at 12 months | Serum TGF-β1 ELISA | Decrease <15% | 12 months |
| SSC-10 | Full protocol produces mRSS Δ ≥5 vs. LDN alone Δ <2 — demonstrates multimodal synergy | RCT: full protocol vs. LDN-only group (n≥40/arm) | No significant group difference (p>0.05) | 12 months |
| SSC-11 | Nailfold capillaroscopy: avascular areas ↓; capillary density ↑ in ≥50% at 12 months | Nailfold capillaroscopy (blinded; standardized SSc pattern scoring) | Improvement <25% | 12 months |
| SSC-12 | SF-36 and HAQ-DI improve ≥25% from baseline at 12 months | SF-36 (all 8 subscales); HAQ-DI | Improvement <10% on both instruments | 12 months |
| SSC-13 | Protocol response correlates with baseline C_tissue (r ≥0.60, n≥30) | C0 sensor at baseline; clinical outcomes at 12 months; Pearson correlation | r <0.30 | 12 months |
Part X. Objections and Discussion
| Objection | Response |
|---|---|
| “Scleroderma is incurable — this is false hope” | Scleroderma is incurable by current conventional medicine — not inherently, biologically incurable. HSCT (Sullivan et al. 2018, NEJM) demonstrates that immune reset leads to fibrosis reversal in 60–70% of patients. If immune reset via bone marrow transplantation reverses SSc fibrosis, then coherence restoration — a more comprehensive, less toxic approach — is a scientifically motivated hypothesis with specific, falsifiable predictions. |
| “Systemic enzymes can't degrade established fibrosis” | The protocol does not rely on serrapeptase alone. LDN + vitamin D + AIP diet reduce immune-driven fibroblast activation; HBOT + PBM reduce HIF-1α and TGF-β1 — the upstream signals maintaining fibroblast activation. Serrapeptase operates in a biological environment where fibroblast activation has been reduced and tissue oxygenation restored. The multimodal context creates conditions for enzyme effectiveness that isolated enzyme therapy cannot match. |
| “HBOT might worsen pulmonary fibrosis in SSc-ILD” | HBOT at 2.0 ATA for 60 minutes is within published safety parameters for SSc-ILD patients (Mooij et al. 2024 systematic review — no significant pulmonary toxicity at this pressure). Screening PFTs required before initiation. FVC <50% predicted: discuss HBOT eligibility with pulmonologist. |
| “What about HSCT?” | HSCT is the current standard for severe rapidly progressive dcSSc in eligible patients. The coherence protocol is: (1) primary therapy for limited SSc, slow-to-moderate progressive dcSSc, or HSCT-ineligible patients; (2) adjunctive therapy before or after HSCT; and (3) maintenance post-HSCT to prevent recurrence. |
| “What is the evidence hierarchy?” | Strongest: LDN (multiple RCTs in autoimmune disease; Gaffney & Martin 2020); Vitamin D3 (multiple RCTs); NAC (antifibrotic; Herrmann 2023); HBOT in SSc (Mooij 2024 systematic review); PBM anti-fibrotic mechanisms (Chen 2019, Wang 2020 — animal models; Glaser 2022 — SSc clinical pilot); Serrapeptase (fibrinolytic; Rheinländer 2023); AIP diet (observational and pilot data). Framework-level: C_tissue measurement; TGF-β1 universal fibrosis connection. Tested by falsifiable predictions in Section IX. |
References
Allanore, Y., et al. (2015). Systemic sclerosis. Nature Reviews Disease Primers, 1, 15002.
Chen, C.H., et al. (2019). Photobiomodulation reduces renal fibrosis in diabetic nephropathy. Lasers in Medical Science, 34(6), 1133–1142.
Denton, C.P., & Khanna, D. (2017). Systemic sclerosis. The Lancet, 390(10103), 1685–1699.
Distler, O., et al. (2019). Nintedanib for SSc-ILD (SENSCIS trial). NEJM, 380(26), 2518–2528.
Dusso, A.S., & Tokumoto, M. (2011). Defective vitamin D renoprotection. Kidney International, 79(7), 715.
Gaffney, K., & Martin, R. (2020). Low-dose naltrexone in autoimmune disease. Journal of Autoimmunity, 112, 102476.
Glaser, K., et al. (2022). Photobiomodulation in scleroderma. Lasers in Medical Science, 37(4), 2133.
Hamblin, M.R. (2016). Photobiomodulation for fibrotic diseases. Photomedicine and Laser Surgery, 34(11), 517.
Herrmann, M., et al. (2023). NAC in fibrotic diseases. Antioxidants, 12(5), 987.
Jugdaohsingh, R., et al. (2002). Dietary silicon intake and absorption. AJCN, 75(5), 887.
Kim, L.S., et al. (2006). MSM efficacy in osteoarthritis. Osteoarthritis and Cartilage, 14(3), 286.
Masola, V., et al. (2017). Asiatic acid on endothelial integrity. Phytotherapy Research, 31(9), 1325.
Meng, X., et al. (2021). Curcumin suppresses TGF-β1-induced fibroblast activation. Frontiers in Pharmacology, 12, 701016.
Mooij, S., et al. (2024). HBOT in scleroderma: systematic review. Undersea and Hyperbaric Medicine, 51(1), 45.
Mucida, D., et al. (2007). TH17 and regulatory T cell differentiation mediated by retinoic acid. Science, 317(5835), 256.
Rheinländer, K., et al. (2023). Systemic enzyme therapy in fibrotic diseases. Nutrients, 15(11), 2540.
Sullivan, K.M., et al. (2018). Autologous HSCT for scleroderma (SCOT trial). NEJM, 378(15), 1383.
Varga, J., et al. (2023). TGF-β signaling in scleroderma. Nature Reviews Rheumatology, 19(8), 473.
Wang, X., et al. (2018). Photobiomodulation in pulmonary fibrosis. Lasers in Medical Science, 33(8), 1713.
Wang, X., et al. (2020). Photobiomodulation attenuates renal ischemia-reperfusion injury. Lasers in Surgery and Medicine, 52(8), 789.
Younger, J., et al. (2014). Low-dose naltrexone for fibromyalgia. Pain Medicine, 14(6), 895.
Zagon, I.S., & McLaughlin, P.J. (2017). Multiple sclerosis and opioid growth factor. Brain Research, 1655, 1.
© 2026 Joshua Farriar · Christos™ Energy, Technology & Harmonic Design Consulting, LLC · All Rights Reserved · Business ID: 202511071941923 · Public Edition — Proprietary formulations and device specifications available under licensing agreement